Jörg Neermann

Jörg Neermann, PhD, joined LSP as a Partner in the Munich Office in early 2007 and serves as member of the supervisory board of Affimed Therapeutics (D), Vivendy (CH) and Curetis (D) and is an observer to the supervisory board of Probiodrug (D). He started his venture capital career in 1996 at Atlas Venture, where he was a key member of the international life sciences team. In 1998, Dr. Neermann joined DVC Deutsche Venture Capital to develop and build the life sciences activities DVC. In 2002, he became DVC’s Managing Partner, with responsibility for the overall investment strategy and operations. In that capacity he served on the boards of e.g. Topotarget A/S, G2M AG, Epigenomics AG, 4SC AG, Probiodrug AG, Keyneurotek AG and was involved in numerous transactions from seed financing to IPO or trade sale. Jörg holds an M.S. and a Ph.D. degree in biotechnology, which he studied at the TU Braunschweig and at M.I.T., Cambridge. He also studied economics at Harvard Business School and at the TU Braunschweig. During his time as a Ph.D. student at the German National Research Institute for Biotechnology (GBF), Jörg was also worked for a strategic management consultancy firm.